Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Myelodysplastic Syndromes
Biotech
Agios’ next-gen PK drug fails ph. 2 blood cancer study
Agios’ next-gen PK activator failed a phase 2 study in a group of rare blood cancers, but the biopharma is holding out hope in sickle cell disease.
James Waldron
May 29, 2026 9:13am
Novartis axes TIM-3 cancer candidate after phase 3 flop
Jan 31, 2024 6:59am
Faron's latest snapshot suggests antibody has leukemia potential
Jul 19, 2023 8:45am
Jasper pulls out of pivotal blood cancer trial at last minute
Jan 10, 2023 10:20am
Foghorn downgraded to full hold on AML/MDS med clouded by deaths
Aug 23, 2022 10:35am
Pfizer undeterred in CD47 plans as competitors face pitfalls
Jul 28, 2022 3:27pm
